Last updated: 8 April 2020 at 5:54pm EST

Arthur Przybyl Net Worth




The estimated Net Worth of Arthur Przybyl is at least $23 Million dollars as of 13 May 2019. Arthur Przybyl owns over 30,000 units of ANI Pharmaceuticals Inc stock worth over $11,004,634 and over the last 18 years Arthur sold ANIP stock worth over $11,986,253.

Arthur Przybyl ANIP stock SEC Form 4 insiders trading

Arthur has made over 18 trades of the ANI Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Arthur sold 30,000 units of ANIP stock worth $2,102,100 on 13 May 2019.

The largest trade Arthur's ever made was exercising 1,221,258 units of ANI Pharmaceuticals Inc stock on 31 December 2008 worth over $2,698,980. On average, Arthur trades about 30,936 units every 60 days since 2007. As of 13 May 2019 Arthur still owns at least 202,589 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of Arthur Przybyl stock trades at the bottom of the page.



What's Arthur Przybyl's mailing address?

Arthur's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri..., and Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.



What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.



Complete history of Arthur Przybyl stock trades at ANI Pharmaceuticals Inc

Insider
Trans.
Transaction
Total value
Arthur Przybyl
President and CEO
Sale $2,102,100
13 May 2019
Arthur Przybyl
President and CEO
Sale $1,755,016
18 Mar 2018
Arthur Przybyl
President and CEO
Sale $2,473,200
12 Mar 2018
Arthur Przybyl
President and CEO
Option $643,305
1 Mar 2018
Arthur Przybyl
President and CEO
Option $678,020
22 Aug 2016
Arthur Przybyl
President and CEO
Option $104,597
8 Jan 2016
Arthur Przybyl
President and CEO
Option $104,597
8 Jan 2016
Arthur Przybyl
President and CEO
Buy $102,375
12 Nov 2015
Arthur Przybyl
President and CEO
Buy $102,375
12 Nov 2015
Arthur Przybyl
President and CEO
Option $63,600
10 Aug 2015
Arthur Przybyl
President and CEO
Option $31,800
7 May 2015
Arthur Przybyl
President and CEO
Sale $4,725,000
12 Mar 2015
Arthur Przybyl
President and CEO
Buy $26,500
9 Sep 2014


ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: